Onconano
Dallas, US · Founded 2014 · 1 known investors
OncoNano is a clinical-stage oncology company developing cancer therapeutics based on its ON-BOARD polymeric micelle nanotechnology platform, which targets universal tumor markers to deliver anti-tumor payloads to the tumor microenvironment. It is building a pipeline of novel cancer therapies.
Founders & leadership
MP
Melissa PaoloniExecutive
MH
Matthew HeadExecutive
KK
Kartik KrishnanExecutive
JG
Joydeep GoswamiNamed on SEC filing
PD
Paritosh DhawaleNamed on SEC filing
AG
Alvaro GuillemNamed on SEC filing
RS
Ravi SrinivasanNamed on SEC filing
Board
JD
John DyettBoard director
GJ
Gina JonesBoard director
YQ
Yumin QuiBoard director
BG
Brett GiroirBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$115M disclosed across 3 rounds · 2018–2025
▶$12.7MraisedJun 2025 · 25 investors · BiotechnologyRule 506(b)
▶$12.7MraisedJun 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John DyettDirector
- Gina JonesDirector
- Melissa PaoloniExecutive Officer
- Matthew HeadExecutive Officer
- Brett GiroirDirector
- Yumin QuiDirector
- Kartik KrishnanExecutive Officer, Director
- Offering amount
- $12.7M
- Amount sold
- $12.7M
- Sales commissions
- $634.9K
- Placement agents
- Salem Partners LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$68.4MraisedNov 2021 · 27 investors · BiotechnologyRule 506(b)
▶$68.4MraisedNov 2021 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin DriscollExecutive Officer, Director
- Alvaro GuillemDirector
- Yumin QiuDirector
- Matthew HeadExecutive Officer
- John DyettDirector
- Offering amount
- $68.4M
- Amount sold
- $68.4M
- Finders' fees
- $2.5M
- Placement agents
- Salem Partners LLC
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$33.9MraisedApr 2019 · 39 investors · BiotechnologyRule 506(b)
▶$33.9MraisedApr 2019 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joydeep GoswamiDirector
- John DyettDirector
- Matthew HeadExecutive Officer
- Paritosh DhawaleDirector
- Alvaro GuillemDirector
- Ravi SrinivasanExecutive Officer, Director
- Offering amount
- $35.4M
- Amount sold
- $33.9M
- Finders' fees
- $600K
- Placement agents
- Salem Partners LLC
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Onconano do?
- OncoNano is a clinical-stage oncology company developing cancer therapeutics based on its ON-BOARD polymeric micelle nanotechnology platform, which targets universal tumor markers to deliver anti-tumor payloads to the tumor microenvironment. It is building a pipeline of novel cancer therapies.
- Who are Onconano's investors?
- Onconano's investors include Green Park & Golf Ventures.
- How much funding has Onconano raised?
- Onconano has disclosed $115M raised across 3 rounds.
- Where is Onconano headquartered?
- Onconano is headquartered in Dallas, US.